ProCE Banner Activity

Experts Answer HCP Questions on Adjuvant Therapy for Renal Cell Carcinoma

Clinical Thought
Read this commentary on expert responses to questions asked by healthcare professionals during a live webinar on current and emerging adjuvant therapies for patients with localized renal cell carcinoma.

Released: April 13, 2022

Expiration: April 12, 2023

No longer available for credit.

Share

Faculty

Brian A. Costello

Brian A. Costello, MD, MS

Associate Professor of Oncology and Urology
Consultant

Division of Medical Oncology
Mayo Clinic
Rochester, Minnesota

Eric Jonasch

Eric Jonasch, MD

Assistant Professor, Genitourinary Medical Oncology
The University of Texas M.D. Anderson Cancer Center
Houston, Texas

Elizabeth Plimack

Elizabeth Plimack, MD, MS

Assistant Professor
Associate Member
Medical Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Provided by

Provided by National Comprehensive Cancer Network, in partnership with Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Exelixis, Inc.

Merck Sharp & Dohme Corp.

Pfizer, Inc.

Faculty Disclosure

Primary Author

Brian A. Costello, MD, MS

Associate Professor of Oncology and Urology
Consultant

Division of Medical Oncology
Mayo Clinic
Rochester, Minnesota

Brian A. Costello, MD, MS, has no relevant conflicts of interest to report.

Eric Jonasch, MD

Assistant Professor, Genitourinary Medical Oncology
The University of Texas M.D. Anderson Cancer Center
Houston, Texas

Eric Jonasch, MD, has disclosed that he has received funds for research support from Arrowhead, Merck, NiKang, and Novartis and consulting fees from Aveo, Aravive, Eisai, Exelixis, Merck, NiKang, Novartis, and Takeda.

Elizabeth Plimack, MD, MS

Assistant Professor
Associate Member
Medical Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Elizabeth R. Plimack, MD, MS, has disclosed that she has received funds for research support from Astellas, Bristol-Myers Squibb, Genentech/Roche, and Merck Sharp & Dohme and consulting fees from Astellas, AstraZeneca/MedImmune, Aveo, Bristol-Myers Squibb/Medarex, Calithera Biosciences, Genentech, Infinity, Janssen, MEI Pharma, Merck, Pfizer, Regeneron, and Seattle Genetics.